Global Peptide-based Drug Market Size, Status and Forecast 2021-2027

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Peptide-based Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
  • 1.2.2 Injection
  • 1.2.3 Oral
  • 1.2.4 Other
• 1.3 Market by Application
  • 1.3.1 Global Peptide-based Drug Market Share by Application: 2016 VS 2021 VS 2027
  • 1.3.2 Cancer
  • 1.3.3 Metabolic Disorders
  • 1.3.4 Central Nervous System
  • 1.3.5 Other
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Peptide-based Drug Market Perspective (2016-2027)
• 2.2 Peptide-based Drug Growth Trends by Regions
  • 2.2.1 Peptide-based Drug Market Size by Regions: 2016 VS 2021 VS 2027
  • 2.2.2 Peptide-based Drug Historic Market Share by Regions (2016-2021)
  • 2.2.3 Peptide-based Drug Forecasted Market Size by Regions (2022-2027)
• 2.3 Peptide-based Drug Industry Dynamic
  • 2.3.1 Peptide-based Drug Market Trends
  • 2.3.2 Peptide-based Drug Market Drivers
  • 2.3.3 Peptide-based Drug Market Challenges
  • 2.3.4 Peptide-based Drug Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Peptide-based Drug Players by Revenue
  • 3.1.1 Global Top Peptide-based Drug Players by Revenue (2016-2021)
  • 3.1.2 Global Peptide-based Drug Revenue Market Share by Players (2016-2021)
• 3.2 Global Peptide-based Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Peptide-based Drug Revenue
• 3.4 Global Peptide-based Drug Market Concentration Ratio
  • 3.4.1 Global Peptide-based Drug Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Peptide-based Drug Revenue in 2020
• 3.5 Peptide-based Drug Key Players Head office and Area Served
• 3.6 Key Players Peptide-based Drug Product Solution and Service
• 3.7 Date of Enter into Peptide-based Drug Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Peptide-based Drug Breakdown Data by Type

• 4.1 Global Peptide-based Drug Historic Market Size by Type (2016-2021)
• 4.2 Global Peptide-based Drug Forecasted Market Size by Type (2022-2027)

5 Peptide-based Drug Breakdown Data by Application

• 5.1 Global Peptide-based Drug Historic Market Size by Application (2016-2021)
• 5.2 Global Peptide-based Drug Forecasted Market Size by Application (2022-2027)

6 North America

• 6.1 North America Peptide-based Drug Market Size (2016-2027)
• 6.2 North America Peptide-based Drug Market Size by Type
  • 6.2.1 North America Peptide-based Drug Market Size by Type (2016-2021)
  • 6.2.2 North America Peptide-based Drug Market Size by Type (2022-2027)
  • 6.2.3 North America Peptide-based Drug Market Size by Type (2016-2027)
• 6.3 North America Peptide-based Drug Market Size by Application
  • 6.3.1 North America Peptide-based Drug Market Size by Application (2016-2021)
  • 6.3.2 North America Peptide-based Drug Market Size by Application (2022-2027)
  • 6.3.3 North America Peptide-based Drug Market Size by Application (2016-2027)
• 6.4 North America Peptide-based Drug Market Size by Country
  • 6.4.1 North America Peptide-based Drug Market Size by Country (2016-2021)
  • 6.4.2 North America Peptide-based Drug Market Size by Country (2022-2027)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Peptide-based Drug Market Size (2016-2027)
• 7.2 Europe Peptide-based Drug Market Size by Type
  • 7.2.1 Europe Peptide-based Drug Market Size by Type (2016-2021)
  • 7.2.2 Europe Peptide-based Drug Market Size by Type (2022-2027)
  • 7.2.3 Europe Peptide-based Drug Market Size by Type (2016-2027)
• 7.3 Europe Peptide-based Drug Market Size by Application
  • 7.3.1 Europe Peptide-based Drug Market Size by Application (2016-2021)
  • 7.3.2 Europe Peptide-based Drug Market Size by Application (2022-2027)
  • 7.3.3 Europe Peptide-based Drug Market Size by Application (2016-2027)
• 7.4 Europe Peptide-based Drug Market Size by Country
  • 7.4.1 Europe Peptide-based Drug Market Size by Country (2016-2021)
  • 7.4.2 Europe Peptide-based Drug Market Size by Country (2022-2027)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Peptide-based Drug Market Size (2016-2027)
• 8.2 Asia-Pacific Peptide-based Drug Market Size by Type
  • 8.2.1 Asia-Pacific Peptide-based Drug Market Size by Type (2016-2021)
  • 8.2.2 Asia-Pacific Peptide-based Drug Market Size by Type (2022-2027)
  • 8.2.3 Asia-Pacific Peptide-based Drug Market Size by Type (2016-2027)
• 8.3 Asia-Pacific Peptide-based Drug Market Size by Application
  • 8.3.1 Asia-Pacific Peptide-based Drug Market Size by Application (2016-2021)
  • 8.3.2 Asia-Pacific Peptide-based Drug Market Size by Application (2022-2027)
  • 8.3.3 Asia-Pacific Peptide-based Drug Market Size by Application (2016-2027)
• 8.4 Asia-Pacific Peptide-based Drug Market Size by Region
  • 8.4.1 Asia-Pacific Peptide-based Drug Market Size by Region (2016-2021)
  • 8.4.2 Asia-Pacific Peptide-based Drug Market Size by Region (2022-2027)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Peptide-based Drug Market Size (2016-2027)
• 9.2 Latin America Peptide-based Drug Market Size by Type
  • 9.2.1 Latin America Peptide-based Drug Market Size by Type (2016-2021)
  • 9.2.2 Latin America Peptide-based Drug Market Size by Type (2022-2027)
  • 9.2.3 Latin America Peptide-based Drug Market Size by Type (2016-2027)
• 9.3 Latin America Peptide-based Drug Market Size by Application
  • 9.3.1 Latin America Peptide-based Drug Market Size by Application (2016-2021)
  • 9.3.2 Latin America Peptide-based Drug Market Size by Application (2022-2027)
  • 9.3.3 Latin America Peptide-based Drug Market Size by Application (2016-2027)
• 9.4 Latin America Peptide-based Drug Market Size by Country
  • 9.4.1 Latin America Peptide-based Drug Market Size by Country (2016-2021)
  • 9.4.2 Latin America Peptide-based Drug Market Size by Country (2022-2027)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Peptide-based Drug Market Size (2016-2027)
• 10.2 Middle East & Africa Peptide-based Drug Market Size by Type
  • 10.2.1 Middle East & Africa Peptide-based Drug Market Size by Type (2016-2021)
  • 10.2.2 Middle East & Africa Peptide-based Drug Market Size by Type (2022-2027)
  • 10.2.3 Middle East & Africa Peptide-based Drug Market Size by Type (2016-2027)
• 10.3 Middle East & Africa Peptide-based Drug Market Size by Application
  • 10.3.1 Middle East & Africa Peptide-based Drug Market Size by Application (2016-2021)
  • 10.3.2 Middle East & Africa Peptide-based Drug Market Size by Application (2022-2027)
  • 10.3.3 Middle East & Africa Peptide-based Drug Market Size by Application (2016-2027)
• 10.4 Middle East & Africa Peptide-based Drug Market Size by Country
  • 10.4.1 Middle East & Africa Peptide-based Drug Market Size by Country (2016-2021)
  • 10.4.2 Middle East & Africa Peptide-based Drug Market Size by Country (2022-2027)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Sanofi
  • 11.1.1 Sanofi Company Details
  • 11.1.2 Sanofi Business Overview
  • 11.1.3 Sanofi Peptide-based Drug Introduction
  • 11.1.4 Sanofi Revenue in Peptide-based Drug Business (2016-2021)
  • 11.1.5 Sanofi Recent Development
• 11.2 Teva
  • 11.2.1 Teva Company Details
  • 11.2.2 Teva Business Overview
  • 11.2.3 Teva Peptide-based Drug Introduction
  • 11.2.4 Teva Revenue in Peptide-based Drug Business (2016-2021)
  • 11.2.5 Teva Recent Development
• 11.3 Novo Nordisk
  • 11.3.1 Novo Nordisk Company Details
  • 11.3.2 Novo Nordisk Business Overview
  • 11.3.3 Novo Nordisk Peptide-based Drug Introduction
  • 11.3.4 Novo Nordisk Revenue in Peptide-based Drug Business (2016-2021)
  • 11.3.5 Novo Nordisk Recent Development
• 11.4 Takeda
  • 11.4.1 Takeda Company Details
  • 11.4.2 Takeda Business Overview
  • 11.4.3 Takeda Peptide-based Drug Introduction
  • 11.4.4 Takeda Revenue in Peptide-based Drug Business (2016-2021)
  • 11.4.5 Takeda Recent Development
• 11.5 Eli Lilly
  • 11.5.1 Eli Lilly Company Details
  • 11.5.2 Eli Lilly Business Overview
  • 11.5.3 Eli Lilly Peptide-based Drug Introduction
  • 11.5.4 Eli Lilly Revenue in Peptide-based Drug Business (2016-2021)
  • 11.5.5 Eli Lilly Recent Development
• 11.6 AstraZeneca
  • 11.6.1 AstraZeneca Company Details
  • 11.6.2 AstraZeneca Business Overview
  • 11.6.3 AstraZeneca Peptide-based Drug Introduction
  • 11.6.4 AstraZeneca Revenue in Peptide-based Drug Business (2016-2021)
  • 11.6.5 AstraZeneca Recent Development
• 11.7 Novartis
  • 11.7.1 Novartis Company Details
  • 11.7.2 Novartis Business Overview
  • 11.7.3 Novartis Peptide-based Drug Introduction
  • 11.7.4 Novartis Revenue in Peptide-based Drug Business (2016-2021)
  • 11.7.5 Novartis Recent Development
• 11.8 AbbVie
  • 11.8.1 AbbVie Company Details
  • 11.8.2 AbbVie Business Overview
  • 11.8.3 AbbVie Peptide-based Drug Introduction
  • 11.8.4 AbbVie Revenue in Peptide-based Drug Business (2016-2021)
  • 11.8.5 AbbVie Recent Development
• 11.9 Ipsen
  • 11.9.1 Ipsen Company Details
  • 11.9.2 Ipsen Business Overview
  • 11.9.3 Ipsen Peptide-based Drug Introduction
  • 11.9.4 Ipsen Revenue in Peptide-based Drug Business (2016-2021)
  • 11.9.5 Ipsen Recent Development
• 11.10 Ferring
  • 11.10.1 Ferring Company Details
  • 11.10.2 Ferring Business Overview
  • 11.10.3 Ferring Peptide-based Drug Introduction
  • 11.10.4 Ferring Revenue in Peptide-based Drug Business (2016-2021)
  • 11.10.5 Ferring Recent Development
• 11.11 Merck
  • 11.11.1 Merck Company Details
  • 11.11.2 Merck Business Overview
  • 11.11.3 Merck Peptide-based Drug Introduction
  • 11.11.4 Merck Revenue in Peptide-based Drug Business (2016-2021)
  • 11.11.5 Merck Recent Development
• 11.12 The Medicines
  • 11.12.1 The Medicines Company Details
  • 11.12.2 The Medicines Business Overview
  • 11.12.3 The Medicines Peptide-based Drug Introduction
  • 11.12.4 The Medicines Revenue in Peptide-based Drug Business (2016-2021)
  • 11.12.5 The Medicines Recent Development
• 11.13 J & J
  • 11.13.1 J & J Company Details
  • 11.13.2 J & J Business Overview
  • 11.13.3 J & J Peptide-based Drug Introduction
  • 11.13.4 J & J Revenue in Peptide-based Drug Business (2016-2021)
  • 11.13.5 J & J Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer